Anaplastic Thyroid Cancer - Pipeline Review, H2 2014

Published: Sep, 2014 | Pages: 81 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Anaplastic Thyroid Cancer - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Anaplastic Thyroid Cancer - Pipeline Review, H2 2014', provides an overview of the Anaplastic Thyroid Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Anaplastic Thyroid Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anaplastic Thyroid Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Anaplastic Thyroid Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Anaplastic Thyroid Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Anaplastic Thyroid Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Anaplastic Thyroid Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Anaplastic Thyroid Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Anaplastic Thyroid Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Anaplastic Thyroid Cancer Overview 7
Therapeutics Development 8
Pipeline Products for Anaplastic Thyroid Cancer - Overview 8
Pipeline Products for Anaplastic Thyroid Cancer - Comparative Analysis 9
Anaplastic Thyroid Cancer - Therapeutics under Development by Companies 10
Anaplastic Thyroid Cancer - Therapeutics under Investigation by Universities/Institutes 11
Anaplastic Thyroid Cancer - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Anaplastic Thyroid Cancer - Products under Development by Companies 14
Anaplastic Thyroid Cancer - Products under Investigation by Universities/Institutes 15
Anaplastic Thyroid Cancer - Companies Involved in Therapeutics Development 16
GlaxoSmithKline plc 16
Daiichi Sankyo Company, Limited 17
Plexxikon Inc. 18
Exelixis, Inc. 19
OXiGENE, Inc. 20
Genelux Corporation 21
Immune Pharmaceuticals, Inc. 22
Anaplastic Thyroid Cancer - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Combination Products 24
Assessment by Target 25
Assessment by Mechanism of Action 28
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
fosbretabulin tromethamine - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
efatutazone - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
cabozantinib s-malate - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
crolibulin - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
(dabrafenib mesylate + trametinib dimethyl sulfoxide) - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
PLX-8394 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
GLONC-2 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
PLX-4720 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
CLM-3 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
CLM-94 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
AY-4 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Anaplastic Thyroid Cancer - Recent Pipeline Updates 55
Anaplastic Thyroid Cancer - Product Development Milestones 73
Featured News & Press Releases 73
Jun 10, 2013: Oxigene Announces Publication Of Final FACT Study Data Of Zybrestat In Patients With Anaplastic Thyroid Cancer In Journal Thyroid 73
Apr 18, 2013: Combination Therapy Shows Promise Against Anaplastic Thyroid Cancer, Study Finds 74
Feb 14, 2013: Eisai's Thyroid Cancer Drug Candidate Lenvatinib Obtains FDA Orphan Drug Status 75
Jan 08, 2013: Combination Of Pazopanib And Paclitaxel May Slow Anaplastic Thyroid Cancer, Mayo Clinic Study Shows 75
Sep 17, 2012: OXiGENE Announces Agreement With FDA On Special Protocol Assessment For Phase III Trial Of Zybrestat In Anaplastic Thyroid Cancer 76
Sep 07, 2012: Oxigene To Present Data Showing Importance Of Local Site Pathology Confirmation In Phase II/III Clinical Trial Of Zybrestat In Anaplastic Thyroid Cancer 76
Sep 02, 2012: Azanta Pharma And Lavi Enter Into Agreement To Provide Zybrestat In Israel On Compassionate Use Basis 77
Aug 22, 2012: OXiGENE Expands ZYBRESTAT Named Patient Program With Azanta 78
Oct 31, 2005: FDA Grants ZD6474 (Zactima) Orphan Drug Designation For The Investigation Of Rare Forms Of Thyroid Cancer 78
Appendix 80
Methodology 80
Coverage 80
Secondary Research 80
Primary Research 80
Expert Panel Validation 80
Contact Us 81
Disclaimer 81

List of Tables
Number of Products under Development for Anaplastic Thyroid Cancer, H2 2014 8
Number of Products under Development for Anaplastic Thyroid Cancer - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 10
Number of Products under Investigation by Universities/Institutes, H2 2014 11
Comparative Analysis by Clinical Stage Development, H2 2014 12
Comparative Analysis by Early Stage Development, H2 2014 13
Products under Development by Companies, H2 2014 14
Products under Investigation by Universities/Institutes, H2 2014 15
Anaplastic Thyroid Cancer - Pipeline by GlaxoSmithKline plc, H2 2014 16
Anaplastic Thyroid Cancer - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 17
Anaplastic Thyroid Cancer - Pipeline by Plexxikon Inc., H2 2014 18
Anaplastic Thyroid Cancer - Pipeline by Exelixis, Inc., H2 2014 19
Anaplastic Thyroid Cancer - Pipeline by OXiGENE, Inc., H2 2014 20
Anaplastic Thyroid Cancer - Pipeline by Genelux Corporation, H2 2014 21
Anaplastic Thyroid Cancer - Pipeline by Immune Pharmaceuticals, Inc., H2 2014 22
Assessment by Monotherapy Products, H2 2014 23
Assessment by Combination Products, H2 2014 24
Number of Products by Stage and Target, H2 2014 27
Number of Products by Stage and Mechanism of Action, H2 2014 30
Number of Products by Stage and Route of Administration, H2 2014 32
Number of Products by Stage and Molecule Type, H2 2014 34
Anaplastic Thyroid Cancer Therapeutics - Recent Pipeline Updates, H2 2014 55